Trump's Trade Bombshell: 250% Tariffs on Drugs, India Imports Face New Levies

In a CNBC interview on August 5, former President Donald Trump unveiled aggressive trade plans that could upend global supply chains:

1. Staggered Drug Tariffs: Up to 250%

• Phase 1: "Small tariffs" on imported pharmaceuticals.

• Phase 2: Rates escalate to 150% within 12–18 months, then peak at 250%.

• Claim: Aims to "lower drug prices and boost U.S. national security."

• Reality Check:

• U.S. pharma giants (J&J, Lilly, AstraZeneca) are scrambling to invest $250B+ in domestic production to avoid tariffs.

• Experts warn: U.S. manufacturing costs (labor, energy) will keep prices high. Generic drugmakers may exit the market, worsening shortages.

2. India Tariff Hike: Imminent

• Trigger: India’s continued Russian oil imports and resale profits.

• Current rate: 25% on select goods.

• New rate: "Substantially" higher (TBD within 24 hours).

• India’s defiance: Refiners still buying Russian crude due to cost advantages.

3. Semiconductor Tariffs Looming

• Expected announcement: Next week. Details remain undisclosed.

Global Fallout

• EU pauses retaliation: Suspended August 7 tariffs on U.S. goods to continue negotiations, but member states criticize the deal as "weak."

• Pharma chaos: Drug prices may spike as tariffs clash with FDA’s 80% import-dependent supply chain.

Key Takeaways:

• U.S. drug consumers face a lose-lose: tariffs → either higher prices or shortages.

• India trade war escalates amid BRICS-aligned energy deals.

• Tech sector braces for semiconductor tariff shocks.